Analysis of the key themes driving private equity deal activity reveals that artificial intelligence accounted for three pharmaceutical deals announced in Q3 2024, worth a total value of $4.2m. The $4.2m investment by Anges Quebec, AQC Capital, ballas Invest, BDC Capital and Deep Divers in Carre Technologies was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, artificial intelligence-related deal activity increased by 50% in Q3 2024 compared with the previous quarter’s total of $2.8m and fell by 100% as compared to Q3 2023. Related deal volume increased by 200% in Q3 2024 versus the previous quarter and was 25% lower than in Q3 2023.
The top-ranked financial advisors supporting these private equity deals in 9M 2024 were Raymond James Financial; Brentwood Capital Advisors; Citizens Financial Group with 2, 1, 1 deals respectively.
The top-ranked legal advisors supporting these private equity deals in 9M 2024 were Bass, Berry & Sims; Choate Hall & Stewart; Morris, Manning & MartinLLP with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2024 – Strategic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.